RecruitingPhase 2NCT06094881
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
Studying Immune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Principal Investigator
- Lei Zhang, MDChinese Academy of Medical Science and Blood Disease Hospital
- Intervention
- Obinutuzumab Injection [Gazyva](drug)
- Enrollment
- 60 enrolled
- Eligibility
- 12-18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06094881 on ClinicalTrials.govOther trials for Immune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07206758Phase I Study of SHR-2173 Injection in Patients With Primary Immune ThrombocytopeniaGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE1NCT07083960OM336 in Autoimmune CytopeniasOuro Medicines
- RECRUITINGPHASE4NCT07133659Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot StudyAl-Mustansiriyah University
- RECRUITINGPHASE1NCT06943937A Clinical Study of YTS109 Cell in R/R Systemic Lupus ErythematosusChina Immunotech (Beijing) Biotechnology Co., Ltd.
- RECRUITINGNCT06727669Longitudinal Cohort of Thrombosis and Hemostasis DiseasesPeking University People's Hospital
- RECRUITINGPHASE2NCT06281327Avatrombopag in the Treatment of Pediatric Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGPHASE2NCT06199089A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05757570An Open-label Study of Povetacicept in Participants With Autoimmune CytopeniasAlpine Immune Sciences, Inc.